Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Endocrine ; 54(1): 55-59, 2016 Oct.
Article in English | MEDLINE | ID: mdl-26876532

ABSTRACT

Several studies reported somatic mutations of many genes (MEN1, CTNNB1, CDKIs and others) in parathyroid adenoma, although with different prevalence. Recently, activating mutations of the EZH2 and ZFX oncogenes were identified in benign parathyroid adenoma by whole exome sequencing. The same mutations had been found in blood and ovary malignant tumours. On one hand, this result raised the hypothesis that these oncogenes may play a role in the onset of parathyroid tumour, but it would also suggest they may be involved in malignant, rather benign, parathyroid neoplasm. Our aim was to verify the occurrence of selected mutations of the EZH2 and ZFX genes in an Italian cohort of 23 sporadic parathyroid carcinomas, 12 atypical and 45 typical adenomas. DNA was extracted from paraffin-embedded tissues, PCR amplified and directly sequenced. No mutations were detected in the coding sequence and boundaries of both genes in any of the samples. Two polymorphisms of the EZH2 gene were identified with different prevalence: the rs2072407 variant was present in the 30 % of the samples, in keeping with the overall frequency in larger populations, while the rs78589034 variant, located close to the 5' end of the exon 16, was detected in only one proband with familial isolated hyperparathyroidism; we investigated the possible outcome on the splicing process. EZH2 and ZFX genes do not seem to have an impact on the onset of most parathyroid tumours, both benign and malignant, though further studies on larger cohorts of different ethnicity are needed.


Subject(s)
Adenoma/genetics , Carcinoma/genetics , Enhancer of Zeste Homolog 2 Protein/genetics , Hyperparathyroidism/genetics , Kruppel-Like Transcription Factors/genetics , Parathyroid Neoplasms/genetics , Adenoma/pathology , Alleles , Carcinoma/pathology , Female , Gene Frequency , Genetic Association Studies , Genetic Predisposition to Disease , Humans , Hyperparathyroidism/pathology , Middle Aged , Mutation , Oncogenes/genetics , Parathyroid Glands/pathology , Parathyroid Neoplasms/pathology
2.
Cell Oncol (Dordr) ; 37(4): 281-8, 2014 Aug.
Article in English | MEDLINE | ID: mdl-25113791

ABSTRACT

PURPOSE: The CDC73 gene, encoding parafibromin, has been identified as a tumour suppressor gene both in hyperparathyroidism-jaw tumour (HPT-JT) syndrome and in sporadic parathyroid carcinoma. While the vast majority of CDC73 mutations affect the N-terminus or the central core of the encoded protein, as yet few mutations have been reported affecting the C-terminus. Here, we report a case (Caucasian female, 28 years) with an invasive ossifying fibroma of the left mandible and hyperparathyroidism (sCa = 16 mg/dl, PTH = 660 pg/mL) due to a parathyroid lesion of 20 mm, hystologically diagnosed as carcinoma. METHODS: The whole CDC73 gene was screened for the presence of mutations by Sanger sequencing. Immunohistochemistry, in vitro functional assays, Western blotting, MTT assays and in-silico modelling were performed to assess the effect of the detected mutation. RESULTS: Sequence analysis of the CDC73 gene in the proband revealed the presence of a novel deletion affecting the C-terminus of the encoded protein (c.1379delT/p.L460Lfs*18). Clinical and genetic analyses of the available relatives led to the identification of three additional carriers, one of whom was also affected by a parathyroid lesion. Immunohistochemistry, Western blotting, MTT and in-silico modelling assays revealed that the deletion leads to down-regulation of the mutated protein, most likely through a proteasome-mediated pathway. We also found that the deletion may cause a conformational change in the C-terminus of the protein, possibly affecting its interaction with partner proteins. Finally, we found that the mutant protein enhances cellular growth. CONCLUSIONS: We report a novel mutation in the CDC73 gene that may underlie HPT-JT syndrome. This mutation appears to affect the C-terminal moiety of the encoded protein, which is thought to interact with other protein partners. The identification of these partners may be instrumental for our understanding of the CDC73-associated phenotype.


Subject(s)
Adenoma/genetics , Fibroma/genetics , Hyperparathyroidism/genetics , Jaw Neoplasms/genetics , Mutation/genetics , Tumor Suppressor Proteins/genetics , Tumor Suppressor Proteins/metabolism , Adult , Cell Line , Female , Germ-Line Mutation/genetics , Humans , Italy , Male , Protein Structure, Secondary , Tumor Suppressor Proteins/chemistry
3.
Article in English | MEDLINE | ID: mdl-18255918

ABSTRACT

An image can be regarded as a fuzzy subset of a plane. A fuzzy entropy measuring the blur in an image is a functional which increases when the sharpness of its argument image decreases. We generalize and extend the relation "sharper than" between fuzzy sets in view of implementing the properties of a relation "sharper than" between images. We show that there are infinitely many implementations of this relation into an ordering between fuzzy sets (equivalently, images). Relying upon these orderings, we construct classes of fuzzy entropies which are useful for image thresholding by cost minimization. Assuming the image to be a degraded version of an ideal two level image (object/background), a fuzzy entropy can be introduced in a cost functional to force the fitting function to be as close as possible to a two-valued function. The minimization problem is numerically solved, and the results obtained on a synthetic image are reported.

4.
Anticancer Res ; 14(2B): 739-45, 1994.
Article in English | MEDLINE | ID: mdl-7516642

ABSTRACT

Authors present a review of the intracavitary treatment of malignant effusions in cancer patients, experience with tetracycline, mechloretamine, quinacrine, radio-isotopes, interferon beta and interferon alpha are reviewed. Personal experience with interferon alpha is reported.


Subject(s)
Ascitic Fluid/therapy , Neoplasms/physiopathology , Pleural Effusion/therapy , Bleomycin/therapeutic use , Humans , Interferon alpha-2 , Interferon-alpha/therapeutic use , Interferon-beta/therapeutic use , Mechlorethamine/therapeutic use , Neoplasms/therapy , Quinacrine/therapeutic use , Recombinant Proteins , Tetracycline/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...